Related Experiment Video
Updated: Jun 13, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Current endovascular treatment of acute stroke and future aspects
Monika Killer1, Gunther Ladurner, Alexander B Kunz
1Christian Doppler University Clinic Salzburg, Ignaz Harrer Strasse 79, 5020 Salzburg, Austria. m.killer@salk.at
Insights
Acute ischemic stroke treatment has expanded beyond intravenous tissue-type plasminogen activator (tPA) to include interventional therapies. New pharmacological and mechanical options offer improved outcomes for stroke patients.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Emergency Medicine
Background:
- Acute ischemic stroke is a leading cause of death and disability.
- Intravenous tissue-type plasminogen activator (tPA) is the primary established therapy.
- Limited patient eligibility and a narrow treatment window restrict tPA use.
Purpose of the Study:
- To review the evolution of acute ischemic stroke treatment.
- To highlight the extended time window for IV tPA based on ECASS III data.
- To introduce emerging interventional, pharmacological, and mechanical therapies.
Main Methods:
- Analysis of data from the European Collaborative Acute Stroke Study (ECASS III).
- Review of current interventional stroke therapies.
- Discussion of novel pharmacological and mechanical treatment options.
Main Results:
- The time window for IV tPA treatment was extended to 4.5 hours post-stroke symptom onset.
- Interventional stroke therapies are crucial for patients outside the extended IV tPA window.
- New treatment strategies are being integrated into routine clinical practice.
Conclusions:
- Treatment options for acute ischemic stroke have significantly advanced.
- Extended IV tPA timelines and interventional therapies improve patient outcomes.
- Ongoing research and development promise further advancements in stroke care.
Abstract:
Acute ischemic stroke remains a condition of high morbidity and mortality. Until now, the only established therapy has been intravenous (IV) tissue-type plasminogen activator (tPA). Only 3-10% of patients with acute ischemic stroke receive this treatment. On the basis of data from part 3 of the European Collaborative Acute Stroke Study (ECASS III), the time window for beneficial treatment of ischemic stroke with IV tPA has been extended from 3 to 4.5h after the onset of stroke symptoms. Beyond that window of opportunity, and additionally to IV treatment, interventional stroke therapy has assumed an important role for the treatment of acute ischemic stroke. Currently, new promising pharmacological and mechanical treatment options are being established as routine procedures to achieve a further improved outcome for stroke patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
